

Date and Time: *Thursday 18th July 2013, 10:00-16:00*

Minutes: Final

Guideline Development Group Meeting

Place: Boardroom, National Clinical Guideline Centre (NCGC), 180 Great Portland Street, London W1W 5QZ

Present: Campbell Cowan (Chair) (CC)
John Campbell (JC)
V-Lin Cheong (VC)
Matthew Fay (MF)
David Fitzmaurice (DF)
Gregory Lip (GL)
Clifford Mann (CM) (Present for notes 4-6)
Eileen Porter (EP)
Suzannah Power (SP)
Rebekah Schiff (RSc)
Richard Schilling (RS)

In attendance:

NICE Staff:	Joanna Ashe (JA) Liz Avital (LA) Clare Jones (CJ) Vicki Pollit (VP)	(Present for notes 3)
NICE attendee 1	Caroline Kier (CK)	(Present for notes 2 –6)

Observers:

NCGC	Saskia Cheyne (SC)	Present for notes 1-3
------	--------------------	-----------------------

Notes

1. CC welcomed the group to the eighth meeting of this GDG. Apologies were received from GC and NM. The Chair asked all GDG members to declare any relevant conflicts of interest.

MF: Non-personal pecuniary interest; meeting in Southampton (Neqas) and London (Impact – Bayer) with logistics and honaria paid by Bayer. Presentation at the commissioning show on AF supported by Inrstar and Roche. Personal non-pecuniary interest; appointed to the NICE Quality Standards Committee as GP representative working with Oberoi consulting with and LUSD project. They are also discussion an AF project.

RS: Non-personal pecuniary interest; received payment for travel and substance from Biosense Webster to Athens for European meeting. Remainder donated to charity.

GL withdrew from the drafting recommendations on bleeding risk tools due to previously declared interests that were deemed a conflict of interest.

The remaining GDG members and NCGC technical team declared no changes.

The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

2. **Clinical and cost effectiveness evidence on referral to specialist AF services:**
CJ and VP presented the clinical and cost effectiveness evidence on referral to specialist AF services.
3. **Clinical and cost effectiveness protocols session:**
The GDG discussed the content of protocols for future clinical evidence reviews.
4. **Clinical and cost effectiveness evidence on bleeding risk tools:**
CJ and VP presented the clinical and cost effectiveness evidence on bleeding risk tools.
5. **Summary of next steps and any other business**
There was no other business.

Date, time and venue of the next meeting

Tuesday 10th September 2013, 10.00-16.00 Boardroom, NCGC offices, 180 Great Portland Street, London, W1W 5QZ.

Wednesday 11th September 2013, 10.00-16.00 Boardroom, NCGC offices, 180 Great Portland Street, London, W1W 5QZ.